Streetbeat News

BCTX

BriaCell Therapeutics Corp.

https://www.briacell.com

Industry

Biotechnology

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Open

3.64

Mkt cap

14M

Volume

126K

High

3.89

P/E Ratio

-0.27

52-wk high

7.87

Low

3.58

Div yield

N/A

52-wk low

0.35

The biotech industry is characterized by long development periods and the need for funding during pre-revenue stages. Success is often marked by promising data, successful trials, or regulatory approval.

Portfolio Pulse from

February 14, 2025 | 12:30 pm

BRIACELL THERAP (BCTX) has formed a hammer chart pattern, suggesting potential support and a possible trend reversal. Additionally, upward revisions in earnings estimates could further bolster the stock's performance.

Portfolio Pulse from

February 11, 2025 | 4:15 pm

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could positively impact the stock price in the short term.

Portfolio Pulse from

February 05, 2025 | 6:15 pm

BriaCell is progressing with its Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer. The trial is active at 35 sites, with the primary endpoint being overall survival. Interim data analysis is planned at 144 events, potentially leading to full approval and marketing authorization. Patient enrollment is expected to complete by mid-2025, and no serious adverse events have been reported.